Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia

References

• Van OsJKapurSSchizophreniaLancet2009374969063564519700006
   PubMed Web of Science ®Google Scholar
• LeuchtSTardyMKomossaKAntipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisLancet201237998312063207122560607
   PubMed Web of Science ®Google Scholar
• RobinsonDGWoernerDGMcMenimanMMendelowitzABilderRMSymptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorderAm J Psychiatry2004161347347914992973
   PubMed Web of Science ®Google Scholar
• JääskeläinenEJuolaPHirvonenNA systematic review and meta-analysis of recovery in schizophreniaSchizophr Bull20133961296130623172003
   PubMed Web of Science ®Google Scholar
• KaneJMImproving patient outcomes in schizophrenia: achieving remission, preventing relapse and measuring successJ Clin Psychiatry2013749e1824107769
   PubMedGoogle Scholar
• WiersmaDNienhuisFJSlooffCJGielRNatural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohortSchizophr Bull199824175859502547
   PubMed Web of Science ®Google Scholar
• PinnaFTusconiMBosiaMCriteria for symptom remission revisited: a study of patients affected by schizophrenic or schizoaffective disordersBMC Psychiatry20131323524294839
   PubMed Web of Science ®Google Scholar
• EmsleyRChilizaBAsmalLThe evidence for illness progression after relapse in schizophreniaSchizophr Res20131481–311712123756298
   PubMed Web of Science ®Google Scholar
• AndreasenNCLiuDZiebellSVoraAHoBCRelapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI studyAm J Psychiatry2013170660961523558429
   PubMed Web of Science ®Google Scholar
• Van HarenNEHulshoff PolHESchnackHGFocal grey matter changes in schizophrenia across the course of illness: a 5-year follow-up studyNeuropsychopharmacology200732102057206617327887
   PubMed Web of Science ®Google Scholar
• HaddadPMBrainCScottJNonadherence with antipsychotic medication in schizophrenia: challenges and management strategiesPatient Relat Outcome Meas20145436225061342
   PubMedGoogle Scholar
• HigashiKMedicGLittlewoodKJMedication adherence in schizophrenia: factors influencing adherence and consequences of non-adherence: a systematic literature reviewTher Adv Psychopharmacol20133420021824167693
   PubMedGoogle Scholar
• LacroJPBunnLBDolderCRLeckbandSGJesteDVPrevalence and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry2002631089290912416599
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• Asher-SvanumHPengXFariesDMontgomeryWHaddadPMTreatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patientsBMC Psychiatry200994619640279
   PubMed Web of Science ®Google Scholar
• HeresSHamannJKissilingWLeuchtSAttitudes toward antipsychotic depot medicationJ Clin Psychiatry200667121948195317194274
   PubMed Web of Science ®Google Scholar
• OlivaresJMPinalBCinosCComparison of long-acting antipsychotics injection and oral antipsychotics in schizophreniaNeuropsychiatry20111275289
   Google Scholar
• CañasFAlptekinKAzorinJMImproving treatment adherence in your patients with schizophrenia: the STAY initiativeClin Drug Investig201333297107
   PubMed Web of Science ®Google Scholar
• MarcusSZummoJPettitARStoddardJDoshiJAAntipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital dischargeJ Manag Care Spec Pharm201521975476826308223
   PubMed Web of Science ®Google Scholar
• LeuchtCHeresSKaneJMOral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomized long-term trialsSchizophr Res20111271–3839221257294
   PubMed Web of Science ®Google Scholar
• KishimotoTRobenzadehALeuchtCLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophr Bull201440119221323256986
   PubMed Web of Science ®Google Scholar
• KaneJMKishimotoTCorrellCUAssessing the comparative efficacy of long-acting injectable vs oral antipsychotic medications in the prevention of relapses provides a case study in comparative effectiveness research in psychiatryJ Clin Epidemiol2013668 SupplS37S4123849151
   PubMed Web of Science ®Google Scholar
• KishimotoTNittaMBorensteinMKaneJMCorrellCULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studiesJ Clin Psychiatry2013741095796524229745
   PubMed Web of Science ®Google Scholar
• Gonzales-RodriguezACatalanRPenadesRProfile of paliperidone palmitate once-monthly long acting injectable in the management of schizophrenia: long-term safety, efficacy and patient acceptability – a reviewPatient Prefer Adherence2015969570626082620
   PubMedGoogle Scholar
• RavenstijnPRemmerieBSavitzAPharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label studyJ Clin Pharmacol201656333033926189570
   PubMed Web of Science ®Google Scholar
• BewaertsJLiuYGopalSEfficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical TrialJAMA Psychiatry201572883083925820612
   PubMed Web of Science ®Google Scholar
• GopalSVermeulenANandyPPractical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophreniaCurr Med Res Opin201531112043205426306819
   PubMed Web of Science ®Google Scholar
• BerwaertsJLiuYGopalSEfficacy and safety of paliperidone palmitate 3 month formulation: a randomized double blind, placebo controlled study [abstract]Schiz Bull201541Supp 1S302
   Google Scholar
• BerwaertsJLiuYGopalSEfficacy and safety of paliperidone palmitate 3 month formulation: a randomized double blind, placebo controlled studyEuropean Psychiatry201530Supp 1272 Abstract
   Google Scholar
• GopalSVermeulenANandyPPopulation pharmacokinetic simulations of dosing windows and missed doses of paliperidone palmitate 3-month formulation in schizophrenia [abstract]Poster presented at: American Psychiatric Association 168th Annual MeetingMay 16–20, 2015Toronto, Canada
   Google Scholar
• SamtaniMNVereulenAParthaNSwitching scenarios for paliperidone palmitate 3-month formulation in schizophrenia: a population pharmacokinetic simulation-based evaluationPoster presented at: American Psychiatric Association 168th Annual MeetingMay 16–20, 2015Toronto, Canada
   Google Scholar
• SamtaniMNRemmerieBSavitzAPharmacokinetics, safety and tolerability of a single dose of paliperidone palmitate 3-month formulation in patients with schizophrenia [abstract]American Psychiatric Association, 168th Annual MeetingMay 16–20, 2015Toronto, Canada
   Google Scholar
• Invega Trinza (paliperdone palmitate extended release injectable suspension for intramuscular use) [package insert]Titusville, FLJanssen Pharmaceuticals2015
   Google Scholar
• HoughSGopalSVijapurkarUPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res20101162–310711719959339
   PubMed Web of Science ®Google Scholar
• HoughDLindenmayerJPGopalSSafety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaProgr Neuropsychopharmacol Biol Psychiatry200933610221031
   PubMed Web of Science ®Google Scholar
• CoppolaDLiuYGopalSA one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaBMC Psychiatry2012122622455454
   PubMed Web of Science ®Google Scholar
• FleischhackerWWGopalSLaneRA randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaInt J Neuropsychopharmacol201215110711821777507
   PubMed Web of Science ®Google Scholar
• SliwaJKBossieCAFuDJTurkozIAlphsLLong-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaNeuropsychiatr Dis Treat2012837538522956873
   PubMed Web of Science ®Google Scholar
• GopalSXuHBossieCIncidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databasesInt J Clin Pract201468121514152225358867
   PubMed Web of Science ®Google Scholar
• AlphsLMaoLRodriguezSCHulihanJStarrHLDesign and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophreniaJ Clin Psych2014751213881393
   Google Scholar
• ZhangFSiTChiouCFEfficacy, safety and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaNeuropsychiatr Dis Treat20151165766825792835
   PubMed Web of Science ®Google Scholar
• TaylorDOlofinjanaOLong-action paliperidone palmitate – interim results of an observational study of its effects on hospitalizationInt Clin Psychopharmacol201429422923424419004
   PubMed Web of Science ®Google Scholar
• SchreinerABergmansPCherubinPA prospective flexible-dose study of paliperidone palmitate in non-acute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agentsClin Ther2014361013721388.e125444566
   PubMed Web of Science ®Google Scholar
• HargarterLCherubinPBergmansPIntramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychoticsProgr Neuropsychopharmacol Biol Psychiatry20155817
   PubMed Web of Science ®Google Scholar
• BeseniusCClark-CarterDNolanPHealth professionals’ attitudes to depot injection antipsychotic medication: a systematic reviewJ Psychiatr Ment Health Nurs201017545246220584242
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 Suppl15615000267
   PubMed Web of Science ®Google Scholar
• VelliganDJWidenPJSajatovicMStrategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelinesJ Psychiatr Pract201016530632420859108
   PubMed Web of Science ®Google Scholar
• AltamuraACAgugliaEBassiMRethinking the role of long-acting atypical antipsychotics in the community settingInt J Clin Psychopharmacol2012276336349
   PubMed Web of Science ®Google Scholar
• StahlSMLong-acting injectable antipsychotics: shall the last be the first?CNS Spectr20141913524512639
   PubMed Web of Science ®Google Scholar
• EmsleyRChilizaBAsmalLMashileMFusar-PoliPLong-acting injectable antipsychotics in early psychosis: a literature reviewEarly Interv Psychiatry20137324725423342964
   PubMed Web of Science ®Google Scholar
• HeresSLambertMVauthRTreatment of early episode in patients with schizophrenia: the role of long acting antipsychoticsEur Psych201429Suppl 214091413
   Google Scholar
• WeydenPJSchoolerNRWeedonJCA randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcomeJ Clin Psychiatry200970101397140619906343
   PubMed Web of Science ®Google Scholar